Logo image of NUWE

NUWELLIS INC (NUWE) Stock Fundamental Analysis

USA - NASDAQ:NUWE - US67113Y7022 - Common Stock

3.57 USD
-0.03 (-0.83%)
Last: 9/25/2025, 10:44:03 AM
Fundamental Rating

3

Taking everything into account, NUWE scores 3 out of 10 in our fundamental rating. NUWE was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While NUWE seems to be doing ok healthwise, there are quite some concerns on its profitability. NUWE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUWE had negative earnings in the past year.
NUWE had a negative operating cash flow in the past year.
NUWE had negative earnings in each of the past 5 years.
In the past 5 years NUWE always reported negative operating cash flow.
NUWE Yearly Net Income VS EBIT VS OCF VS FCFNUWE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

NUWE's Return On Assets of -140.57% is on the low side compared to the rest of the industry. NUWE is outperformed by 85.26% of its industry peers.
The Return On Equity of NUWE (-274.93%) is worse than 76.32% of its industry peers.
Industry RankSector Rank
ROA -140.57%
ROE -274.93%
ROIC N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
NUWE Yearly ROA, ROE, ROICNUWE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Gross Margin of NUWE (63.18%) is better than 64.74% of its industry peers.
NUWE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NUWE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
NUWE Yearly Profit, Operating, Gross MarginsNUWE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NUWE has more shares outstanding than it did 1 year ago.
NUWE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NUWE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NUWE Yearly Shares OutstandingNUWE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
NUWE Yearly Total Debt VS Total AssetsNUWE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

NUWE has an Altman-Z score of -62.29. This is a bad value and indicates that NUWE is not financially healthy and even has some risk of bankruptcy.
NUWE's Altman-Z score of -62.29 is on the low side compared to the rest of the industry. NUWE is outperformed by 94.21% of its industry peers.
NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -62.29
ROIC/WACCN/A
WACC8.76%
NUWE Yearly LT Debt VS Equity VS FCFNUWE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

NUWE has a Current Ratio of 2.23. This indicates that NUWE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NUWE (2.23) is comparable to the rest of the industry.
NUWE has a Quick Ratio of 1.59. This is a normal value and indicates that NUWE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.59, NUWE is in line with its industry, outperforming 43.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.59
NUWE Yearly Current Assets VS Current LiabilitesNUWE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

NUWE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -191.34%.
Looking at the last year, NUWE shows a decrease in Revenue. The Revenue has decreased by -1.25% in the last year.
NUWE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.67% yearly.
EPS 1Y (TTM)-191.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38%
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%2.53%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, NUWE will show a very strong growth in Revenue. The Revenue will grow by 45.06% on average per year.
EPS Next Y99.74%
EPS Next 2Y41.38%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year2.8%
Revenue Next 2Y24.85%
Revenue Next 3Y35.82%
Revenue Next 5Y45.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NUWE Yearly Revenue VS EstimatesNUWE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
NUWE Yearly EPS VS EstimatesNUWE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -200M -400M -600M -800M -1B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NUWE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUWE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUWE Price Earnings VS Forward Price EarningsNUWE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUWE Per share dataNUWE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600

4.3 Compensation for Growth

A more expensive valuation may be justified as NUWE's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.38%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

NUWE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUWELLIS INC

NASDAQ:NUWE (9/25/2025, 10:44:03 AM)

3.57

-0.03 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners1.28%
Inst Owner Change144.34%
Ins Owners0.02%
Ins Owner Change99.63%
Market Cap3.21M
Analysts82.86
Price TargetN/A
Short Float %2.45%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.3%
Min EPS beat(2)-59.6%
Max EPS beat(2)10.99%
EPS beat(4)2
Avg EPS beat(4)15.13%
Min EPS beat(4)-124.14%
Max EPS beat(4)233.27%
EPS beat(8)5
Avg EPS beat(8)18.63%
EPS beat(12)7
Avg EPS beat(12)13.66%
EPS beat(16)10
Avg EPS beat(16)12.63%
Revenue beat(2)0
Avg Revenue beat(2)-12.68%
Min Revenue beat(2)-17.82%
Max Revenue beat(2)-7.53%
Revenue beat(4)1
Avg Revenue beat(4)-4.89%
Min Revenue beat(4)-17.82%
Max Revenue beat(4)7.39%
Revenue beat(8)2
Avg Revenue beat(8)-4.25%
Revenue beat(12)4
Avg Revenue beat(12)-5.2%
Revenue beat(16)6
Avg Revenue beat(16)-5.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-777
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-10.33
FCFYN/A
OCF(TTM)-10.29
OCFYN/A
SpS9.76
BVpS3.98
TBVpS3.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.57%
ROE -274.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.18%
FCFM N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
F-Score5
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.1%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 1.59
Altman-Z -62.29
F-Score5
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)40.1%
Cap/Depr(5y)48.83%
Cap/Sales(3y)1.63%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-191.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38%
EPS Next Y99.74%
EPS Next 2Y41.38%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%2.53%
Revenue Next Year2.8%
Revenue Next 2Y24.85%
Revenue Next 3Y35.82%
Revenue Next 5Y45.06%
EBIT growth 1Y43.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.61%
OCF growth 3YN/A
OCF growth 5YN/A